Description
Binimetinib, marketed under the brand name MEKTOVI, It is an prescription medication that has been approved binimetinib (Mektovi) in combination with encorafenib (Braftovi) on June 27, 2018. The combination was approved for treating patients with unresectable or metastatic melanoma that has a BRAF V600E or V600K mutation.
What is MEKTOVI (binimetinib) ?
MEKTOVI is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adults and children with:
B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
How to order approved “MEKTOVI (binimetinib) for tablets” Medicine?
MEKTOVI (Binimetinib) tablets is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing MEKTOVI and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
